Chiesi Keen To Nurture Disruptive Innovation
Italian Group Raising International Profile
Chiesi may not be a big pharma giant but it is very good at spotting early-stage innovative projects and partnering with the likes of Moderna, Protalix and Bioasis to tackle respiratory and rare diseases, CEO Ugo Di Francesco tells Scrip.
You may also be interested in...
The world is waiting for Moderna’s COVID-19 vaccine results, but meanwhile the company is exploring new avenues to secure long-term growth
The latest in a series of deals that Boehringer Ingelheim has inked in the oncology space will see the German family-run firm acquire US biotech Abexxa.
The Basel-based major has swooped to buy fellow Swiss group Arctos in the belief that optogenetics is a promising therapeutic approach that might restore sight to patients who are legally blind.